



## Zymeworks and XOMA to Collaborate on Antibody Research Program

May 15, 2009

**VANCOUVER, British Columbia, Canada** – Zymeworks Inc., a privately held computational biotechnology company, today announced it has entered into a research agreement with California-based XOMA Ltd. (Nasdaq: XOMA, [www.xoma.com](http://www.xoma.com)) to optimize an undisclosed antibody using Zymeworks' ZymeCAD™ suite of predictive protein engineering tools and XOMA's innovative Targeted Affinity Enhancement™ (TAE™) technology for antibody mutagenesis and optimization. Financial terms are not disclosed.

“XOMA is a recognized leader in the field of antibody optimization and expression, as evidenced by their contributions to the development of marketed antibody therapeutics with Genentech, Inc. (LUCENTIS®) and UCB S.A. (CIMZIA®),” says Ali Tehrani, Ph.D., President and CEO of Zymeworks Inc. “We are excited to collaborate with XOMA on this antibody optimization project. Furthermore, we believe that this collaboration will showcase Zymeworks' capabilities in protein optimization and engineering for the development of second-generation biologics and therapeutic antibodies.”

“The Zymeworks technology represents a new tool for researchers and developers to optimize the properties of therapeutic proteins,” said Stephen K. Doberstein, Ph.D., XOMA's Vice President of Research. “We look forward to applying this advanced technology in one of our antibody engineering programs.”

### **About Zymeworks Inc.**

Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop protein therapeutics. Zymeworks' proprietary ZymeCAD™ molecular simulation platform creates a highly detailed modeling environment that generates novel physical and chemical insights into protein systems. Zymeworks' protein engineers utilize these new understandings of structure-function relationships to modify proteins to address the needs of strategic partners and to advance Zymeworks' protein therapeutics pipeline. More information on Zymeworks can be found at <http://www.zymeworks.com>.

Contact:

Zymeworks Inc.

David Poon, Ph.D.

Manager, Business Development

[info@zymeworks.com](mailto:info@zymeworks.com)

Source: Zymeworks Inc.